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Abstract
Background: Tumor necrosis factor-a (TNF-a) and
interleukin-1b (IL-1b), produced by endotoxin-activat-
ed Kupffer cells, play a key role in the pathogenesis
of alcoholic liver cirrhosis (ALC). Alleles TNFA –238A,
IL1B –31T and variant IL1RN*2 of repeat polymor-
phism in the gene encoding the IL-1 receptor antagon-
ist increase production of TNF-a and IL-1b, respec-
tively. Alleles CD14 –159T, TLR4 c.896G and TLR4
c.1196T modify activation of Kupffer cells by endotox-
in. We confirmed the published associations between
these common variants and genetic predisposition
to ALC by means of a large case-control association
study conducted on two Central European
populations.
Methods: The study population comprised a Czech
sample of 198 ALC patients and 370 controls (MONI-
CA project), and a German sample of 173 ALC
patients and 331 controls (KORA-Augsburg), and 109
heavy drinkers without liver disease.
Results: Single locus analysis revealed no significant
difference between patients and controls in all tested
loci. Diplotype wIL1RN*2/*2; IL1B –31Tqx was associ-
ated with increased risk of ALC in the pilot study, but
not in the validation samples.
Conclusions: Although cytokine mediated immune
reactions play a role in the pathogenesis of ALC,
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hereditary susceptibility caused by variants in the
corresponding genes is low in Central European
populations.
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Introduction
Recent studies on epidemiology of alcoholic liver dis-
ease suggest that only 40% of heavy drinkers will
develop steatohepatitis and less than 5% will develop
cirrhosis (1, 2). In addition to the cumulative dose of
alcohol, gender and certain comorbidities including
viral hepatitis and obesity, and yet unidentified genet-
ic factors account for at least 50% of the individual
susceptibility to alcoholic liver cirrhosis (ALC) (3, 4).
Numerous studies have focused on genetic variability
of the genes encoding ethanol metabolizing enzymes,
genes affecting the severity of liver steatosis, oxida-
tive stress and fibrosis, as well as genes modifying
the response to endotoxins (lipopolysaccharide, LPS)
(3, 5). However, the results of candidate gene case-
control studies have been either inconclusive or non-
replicable (6, 7).
The importance of endotoxins and activation of
Kupffer cells in the pathogenesis of ALC is evidenced
by experimental studies in animals (8–10) and
humans (10, 11). Adachi et al. (12, 13) showed that
Kupffer cell inactivation by gadolinium chloride, intes-
tinal sterilization and targeted disruption of the genes
encoding the LPS recognition receptor CD14 and the
toll-like receptor 4 (TLR4) protected the animals from
alcohol induced liver injury (14, 15). Similarly, mice
knocked-out for tumor necrosis factor-a (TnfA) (16),
type I-TnfA receptor (17), or interleukin-1b (IL-1B)
(18) were resistant to alcohol-induced liver damage,
whereas interleukin-1 receptor antagonist (IL1-ra)
knockout mice were more susceptible to alcohol-
derived insults than their wildtype littermates (19).
These data strongly support the crucial role of LPS
receptors and the main inflammatory cytokines pro-
duced by Kupffer cells in mouse models of alcohol
induced injury.
Several functionally relevant genetic variants have
been identified in the genes for CD14, TLR4, tumor
necrosis factor a (TNF-a), IL-1b and IL-1ra in humans.
Accordingly, the –159C/T variation in the promoter of
CD14 enhances production of CD14 by monocytes
(20), whereas two linked variations, c.896A/G and
c.1196C/T, in the coding region of TLR4 impede the
activation of monocytes by LPS (21). The polymor-
phism –238G/A of the TNFA promoter increases the
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transcription of TNF-a (22). The IL1 gene cluster on
chromosome 2 contains IL1B and IL1RN genes, which
encode IL-1b and its receptor antagonist IL-1ra,
respectively (23). The variant –31T in the promoter
of IL1B, which changes the wildtype sequence
–31CATAA to –31TATAA, significantly increases IL-1
transcription (24). The IL1RN gene contains a penta-
allelic 86-bp tandem repeat. The second most com-
mon IL1RN*2 allele containing two repeats increases
the secretion rate of IL-1b in vitro (25). The role of
these variations in susceptibility to alcohol-induced
liver injury has been suggested by several groups
(26–30), with the highest disease risk attributed to the
IL-1 gene cluster polymorphisms in the Asian popu-
lation (27, 28).
In our study, we sought to confirm the published
associations between these common variations and
genetic predisposition to ALC by means of a large
case-control association study conducted on a Central
European (CEU) population.
Materials and methods
Subjects
Primary assessment of allelic frequencies was performed in
a pilot study. Positive associations were confirmed in valid-
ation samples. The study was approved by the institutional
Review Boards of all participating centers. Written informed
consent was obtained from all subjects and the study con-
formed to the declaration of Helsinki Ethical Guidelines.
Pilot study We consecutively included 100 Caucasian
patients with ALC referred to the Institute for Clinical and
Experimental Medicine, Prague, Czech Republic, from March
2004 to October 2005. Their daily alcohol consumption was
more than 40 g in female patients and more than 60 g in
male patients for more than 10 years. The Czech control
group consisted of 180 healthy volunteers without self-
reported history of liver disease. The controls were selected
out of 653 individuals after being ranked by a questionnaire
on reported alcohol consumption, who participated in the
population-based MONICA ( toring of trends and deter-MONI
minants in rdiovascular disease) project between MarchCA
1996 and November 1997 (31).
Validation study For validation purposes, 173 patients with
ALC treated in the Department of Medicine, University of
Erlangen, Germany, and the Department of Medicine, Char-
ite´, Humboldt University Berlin, Germany, were analyzed.
These patients had been recruited between August 1995 and
December 2003. Their daily alcohol consumption was the
same as for the Czech subjects. The German control group
consisted of 331 healthy volunteers without self-reported
history of liver disease. The controls were selected out of
812 individuals drinking 20–40 g of ethanol/day who were
part of a total number of 4261 participants of the S4 survey
of the population-based KORA ( operativeGesundheitsfor-KO
schung in der RIegion AIugsburg) project between 1999 and
2001 (32). In addition, a second German control group con-
sisting of 109 heavy drinkers without liver disease was
included. These patients were admitted between January
1999 and December 2003 to the University of Erlangen,
Germany for alcohol detoxification or for other health-relat-
ed problems, such as infections and accident injuries.
Subjects were assigned to the groups of ALC according to
clinical/laboratory evidence for the presence of cirrhosis
evidenced by simultaneous presence of: a) clinical findings
typical for liver cirrhosis (jaundice, spider naevi, ascites,
encephalopathy), b) abnormal blood tests (abnormal coag-
ulation tests, decreased serum albumin concentration and
platelet count), c) abnormal liver ultrasound, and d) esoph-
ageal varices on upper gastrointestinal endoscopy. In total,
11 (5.6%) Czech and 22 (12.7%) German patients with ALC
who did not meet these criteria underwent liver biopsy due
to presence of cirrhosis. Liver biopsy was not performed in
patients with advanced liver dysfunction (coagulopathy and
ascites) who met the above-mentioned criteria. A total of
83 (42%) Czech and 96 (56%) German patients with ALC
underwent liver transplantation and the diagnosis of liver cir-
rhosis was confirmed in all cases by explanted liver histol-
ogy. Patients with positive serology of hepatitis B or C, high
ferritin and elevated transferrin saturation, anti-nuclear or
anti-mitochondrial antibodies, decreased level of a1-antitryp-
sin and those with suspected liver cancer were excluded.
Heavy drinkers without liver cirrhosis had negative clinical
findings indicating liver disease, normal blood tests and nor-
mal liver ultrasonography. Blood tests were performedwhile
actively drinking and demonstrated normal results for ala-
nine aminotransferase, aspartate aminotransferase, total
bilirubin, albumin, platelet count and prothrombin time. Ele-
vation of g-glutamyltransferase was not an exclusion factor.
None of the heavy drinkers underwent upper gastrointestinal
endoscopy or liver biopsy due to ethical reasons.
The demographic and alcohol exposure data on all studied
groups are summarized in Table 1.
Genotyping
Genomic DNA was isolated from peripheral blood from all
patients using the QIAamp DNA Blood Mini Kit (Qiagen
GmbH, Hilden, Germany). For MONICA and KORA controls,
isolated DNA was obtained. Single nucleotide polymor-
phisms were determined by polymerase chain reaction
(PCR) followed by restriction fragment length (RFLP) analysis
of the products. Genotyping of the IL1RN variable number
of tandem repeats (VNTR) locus was performed by a PCR-
based fragment length polymorphism method (see Table 2).
Restriction endonucleases were purchased from Fermentas
(Fermentas UAB, Vilnius, Lithuania). The PCR products of the
IL1RN VNTR analysis were coded as follows: allele 1s4
repeats (size 442-bp), allele 2s2 repeats (270-bp), allele 3s5
repeats (528-bp), allele 4s3 repeats (356-bp), allele 5s6
repeats (614-bp). The rare alleles 3, 4 and 5, constituting less
than 5% of the IL1RN allelic variants, were grouped in the
statistical analysis.
Samples from cases and controls were included in each
96-sample batch analyzed. In order to minimize genotyping
errors, blank control wells were left on the PCR plates and
assays were wholly re-typed if the call rate was below 90%.
Three operators, unaware of the status of the samples, inde-
pendently performed the genotype assignment. Out of 3762
genotyping analyses performed, approximately 100 (2.7%)
were duplicated due to the discrepancy between oper-
ators. After testing for Hardy-Weinberg equilibrium, allele
frequencies were checked for consistency with data from
the population of European ancestry wUtah Residents with
Northern and Western European Ancestry (CEU)x from the
HapMap database (33).
Statistical analysis
Two-sided power calculations at ps0.05 for 80% statistical
power were performed using the DSTPLAN software (http://
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Table 1 Demographic and alcohol exposure data on patients with ALC, general population controls without cirrhosis and
heavy drinkers without cirrhosis.
Alcoholic liver Controls without Heavy drinkers
cirrhosis cirrhosis without cirrhosis
Czech study population (ns568)
n 198 370 –
Male (%) 149 (75.3) 255 (69.0) –
Age, years, median (IQR) 54 (26–72)a 50 (24–80) –
Alcohol, g/day, median (range) 100 (75–143)a 13 (6–29) –
German study population (ns613)
n 173 331 109
Male (%) 117 (67.6) 222 (67.0) 84 (77.1)
Age, years, median (IQR) 50 (24–71)b 50 (30–69) 43 (22–70)
Alcohol, g/day, median (range) 100 (70–150)c 30 (20–40) 250 (185–335)
ap-0.05 vs. controls without liver cirrhosis; bp-0.05 vs. heavy drinkers without cirrhosis; cp-0.05 vs. controls without liver
cirrhosis and vs. heavy drinkers without cirrhosis. IQR, interquartile range.
Table 2 Genotyped loci in the CD14, TLR4, TNFA, IL1B and IL1RN genes.
Variation Forward primer Tm, 8C Restriction enzyme
Ref. dbSNPa id Reverse primer Time, s Fragment length, bp
CD14 –159C/T 59-TTGGTGCCAACAGATGAGGTTCAC-39 608C HaeIII
rs2569190 59-TTCTTTCCTACACAGCGGCACCC-39 30 s 204, 201, 156
TLR4 c.896A/G 59-GATTAGCATACTTAGACTACTACCTCCATG-39 598C NcoI
rs4986790 59-GATCAACTTCTGAAAAAGCATTCCCAC-39 40 s 223, 26
TLR4 c.1196C/T 59-GGTTGCTGTTCTCAAAGTGATTTTGGGAGAA-39 558C HinfI
rs4986791 59-ACCTGAAGACTGGAGAGTGAGTTAAATGCT-39 40 s 378, 29
TNFA –238 G/A 59-GCCCCTCCCAGTTCTAGTTC-39 628C BamHI
rs361525 59-CTCACACTCCCCATCCTCCCGGATC-39 30 s 185, 26
IL1B –31 C/T 59-CCCTTCCATGAACCAGAGAA-39 608C AluI
rs1143627 59-GCTGAAGAGAATCCCAGAGC-39 30 s 97, 87, 54
IL1B –511 T/C 59-TGGCATTGATCTGGTTCATC-39 608C AvaI
rs16944 59-GCCCTCCCTGTTCTGTATTGA-39 30 s 190, 60
IL1RN VNTR 59-CCCCTCAGCAACACTCC-39 648C –
156109b 59-GGTCAGAAGGGCAGAGA-39 30 s 442, 270, 528, 356, 614
aNCBI database of genetic variation, www.ncbi.nlm.nih.gov/SNP. bNCBI database of unified sequence tagged sites,
www.ncbi.nih.gov/genome/STS. VNTR, variable number of tandem repeats; Tm, melting temperature.
linkage.rockefeller.edu/soft). The size of the pilot study was
calculated as follows. When the odds ratio (OR) of a poly-
morphism was assumed to be 2, the required sample size
was 100 cases and 180 controls for the polymorphism with
frequency of 0.5 (CD14 –159C/T). When the OR was assumed
to be 4, the same sample size was sufficient to detect a true
effect of a polymorphism with frequency of 0.03 (TNFA
–238G/A). To confirm the association of the wIL1RN*2/*2;
IL1B –31Tqx diplotype with ALC, we calculated the minimal
size of the pilot and validation studies from the observed
haplotype frequencies obtained by investigation of 100
Czech cases and 180 Czech controls and in the extended pilot
study, respectively.
Hardy-Weinberg equilibrium of alleles at individual loci
was evaluated using the program HWE (http://linkage.
rockefeller.edu/soft). Haplotype frequencies for pairs of
alleles were estimated using the software EH based on the
expectation-maximization algorithm (http://linkage.rocke-
feller.edu/soft). Linkage disequilibrium (LD) coefficients
D9sD/Dmin or max and r2 were calculated using the MIDAS soft-
ware (34). Age and median alcohol consumption between
the groups was compared using the Mann-Whitney test.
Male to female ratios were compared using the Fisher exact
test.
All association analyses were performed by logistic
regression analysis using SPSS software version 14.0 (SPSS
Inc., Chicago, IL, USA). Where applicable, logistic regression
analysis adjusted for age was performed. Due to the multiple
testing, the level of significance in the pilot study was set at
p-0.01. In the extended pilot and validation studies, where
only one association was tested, the level of significancewas
set at p-0.05. All p-values were two-sided.
Results
In the control populations, the alleles at the individual
loci were in Hardy-Weinberg equilibrium. The geno-
type frequencies in healthy controls for all polymor-
phisms were in concordance with the reference
HapMap database (33). As the LD between the IL1B
–511 and IL1B –31 loci in 100 Czech patients with ALC
and 180 population controls was perfect (D9s1, r2s1),
we investigated only the IL1B –31 polymorphism in
both the pilot and validation samples. A significant
(p-0.0001) but weak LD (D9-0.5) was found between
the IL1B –31 and IL1RN VNTR loci.
Single locus analysis
Single locus analysis was performed in 100 Czech
patients with ALC and 180 population controls (see
Table 3). The proportion of the TLR4 c.1196T allele
was higher in patients with ALC (8.5%) than in healthy
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Table 3 Genotype frequencies in 100 Czech patients with ALC and 180 Czech healthy controls.
Locus Genotype Patients Controls Association with alcoholic cirrhosis
Unadjusted Adjusted for agen % n %a
p OR (95% CI) p OR (95% CI)
CD14 –159 C/C 21 21.0 31 17.2 1 (reference) 1 (reference)
C/T 43 43.0 82 45.6 0.45 0.77 (0.40–1.51) 0.37 0.73 (0.37–1.45)
T/T 36 36.0 67 37.2 0.51 0.79 (0.40–1.58) 0.49 0.78 (0.36–1.58)
TLR4 c.896 A/A 85 85.0 160 88.8 1 (reference) 1 (reference)
A/G 14 14.0 19 10.6 0.39 1.39 (0.67–2.90) 0.49 1.30 (0.61–2.77)
G/G 1 1.0 1 0.6 0.66 1.88 (0.12–30.5) 0.72 1.67 (0.10–27.2)
TLR4 c.1196 C/C 85 85.0 166 92.2 1 (reference) 1 (reference)
C/T 13 13.0 13 7.2 0.11 1.95 (0.87–4.40) 0.13 1.91 (0.83–4.37)
T/T 2 2.0 1 0.6 0.27 3.90 (0.35–43.7) 0.21 4.79 (0.41–56.6)
TNF –238 G/G 91 91.0 170 94.4 1 (reference) 1 (reference)
G/A 9 9.0 10 5.6 0.28 1.68 (0.66–4.29) 0.28 1.17 (0.65–4.48)
A/A 0 0.0 0 0
IL1B –511 T/T 14 14.0 23 12.8 1 (reference) 1 (reference)
C/T 45 45.0 82 45.6 0.83 0.92 (0.43–1.96) 0.98 1.01 (0.47–2.19)
C/C 41 41.0 75 41.7 0.74 0.88 (0.41–1.89) 0.97 0.98 (0.45–2.16)
IL1B –31 C/C 14 14.0 23 12.8 1 (reference) 1 (reference)
C/T 45 45.0 82 45.6 0.83 0.92 (0.43–1.96) 0.98 1.01 (0.47–2.19)
T/T 41 41.0 75 41.7 0.74 0.88 (0.41–1.89) 0.97 0.98 (0.45–2.16)
IL1RN 1/1 42 42.0 82 45.6 1 (reference) 1 (reference)
1/2 47 47.0 80 44.4 0.49 1.20 (0.72–2.02) 0.37 1.28 (0.75–2.16)
2/2 10 10.0 11 6.4 0.21 1.82 (0.71–4.63) 0.16 1.99 (0.77–5.18)
1/3,4,5 1 1.0 5 2.8 0.25 0.29 (0.03–2.40) 0.42 0.41 (0.05–3.57)
2/3 0 0.0 2 1.1
aThe sum of the percentages may exceed 100% due to rounding. OR, odds ratio; CI, confidence interval.
Table 4 Association of the wIL1RN*2/*2; IL1B –31Tqx diplotype with ALC in patients with ALC, healthy population controls
and heavy drinkers without cirrhosis.
Population Unadjusted Adjusted for age
p OR (95% CI) p OR (95% CI)
Pilot study (100 Czech ALC patients vs. 180 0.006 8.80 (1.86–41.6) 0.005 9.45 (1.96–45.7)
Czech population controls)
Extended pilot study (198 Czech ALC 0.083 2.09 (0.97–4.84) 0.092 2.06 (0.89–4.78)
patients vs. 370 Czech population controls)
Validation I (173 German ALC patients vs. 0.973 0.99 (0.52–1.90) a a
331 German population controls)
Validation II (173 German ALC patients vs. 0.326 1.63 (0.61–4.34) 0.484 1.44 (0.52–3.95)
109 German heavy drinkers without ALC)
aAs there was no age difference between cases and controls, no adjustment for age was performed. OR, odds ratio; CI,
confidence interval; ALC, alcoholic liver cirrhosis.
controls (4.2%), but the association was not signi-
ficant. For the other six loci, no significant differences
in allele or genotype frequency between patients and
controls were found (Table 3). In spite of a better
goodness-of-fit of the regression model, adjustment
for age did not significantly influence the results. Fur-
thermore, genotyping of the TNFA –238A, IL1B –31T,
CD14 –159T and TLR4 c.1196T loci in an extended
sample of 198 Czech ALC patients and 370 Czech con-
trols did not yield any significant association. Speci-
fically, the TLR4 c.1196T locus was not associated
with ALC both in the heterozygous model wOR 1.56,
95% confidence interval (CI) 0.88, 2.78, ps0.13x and
in the homozygous model (OR 3.93, 95% CI 0.35,
43.65, ps0.26).
Haplotype analysis In the pilot study of 100 Czech
patients with ALC and 180 population controls, the
wIL1RN*2/*2; IL1B –31Tqx diplotype, determined by
homozygosity for the IL1RN allele 2 and carriage of
the IL1B –31T allele, was associated with an increased
risk of ALC when compared to other diplotypes in the
IL-1 gene cluster. In total, 9% of cases (compared to
1.1% of controls) revealed this diplotype, with an age-
adjusted OR of 9.45 (95% CI 1.96, 45.7, ps0.005) for
ALC (see Table 4). Although the power of the haplo-
type analysis was 85%, we were aware of the wide CI
for the OR. Therefore, we evaluated the association of
the diplotype in three subsequent steps.
First, we expanded the sample size of Czech
patients and controls. Assuming an OR of 5, a
required sample size of 198 cases and 370 controls
was used. In total, 98 consecutive patients with ALC
from the same center prospectively recruited between
November 2005 and September 2006 were added to
the 100 Czech patients included in the pilot study, and
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the control sample was extended by 190 subjects
from the MONICA study. Thus, the total population
sample comprised 198 patients and 370 controls. The
association of the wIL1RN*2/*2; IL1B –31Tqx diplotype
was not significant; however, it was close (age-adjust-
ed OR 2.06, 95% CI 0.89, 4.78, ps0.09). The non-sig-
nificance could be caused by increased prevalence of
the diplotype in the extended number of controls
(2.8%).
Second, the wIL1RN*2/*2; IL1B –31Tqx diplotype
frequency of German ALC patients was compared to
that of the German population control group. Assum-
ing an OR of 2.5, a required sample size of 173 cases
and 331 controls was used in the validation study. No
association with ALC due to the same prevalence of
the diplotype in patients and controls (8.8% in both
groups) was found.
Finally, the association was further tested in
German patients with ALC and heavy drinkers without
liver disease as controls. Even then, no significant
association was found (see Table 4), and the frequen-
cy of the wIL1RN*2/*2; IL1B –31Tqx diplotype in the
group of healthy heavy drinkers was not significantly
different from that in German population controls
(5.5% vs. 8.8%, ps0.30).
Discussion
In our study, we included only those genes encoding
cytokines whose role in ALC was proved in animal
models and those polymorphisms whose impact on
gene expression or protein function was described in
in vitro studies. Moreover, the included polymor-
phisms have been associated with an increased risk
of alcoholic liver disease (26, 29, 30, 35), accelerated
progression of fibrosis in chronic hepatitis B (36) and
endotoxin hyporesponsiveness in humans (21). To
include gene variants with the largest possible effect
size, we also investigated the wIL1RN*2/*2; IL1B
–31Tqx diplotype, because it increases the production
of IL-1b more than either of the polymorphisms alone
(24, 25). This is enabled by the low strength of LD
which permits the additive effect of both proinflam-
matory alleles (i.e., IL1RN*2 and IL1B –31T) on IL-1b
production. Importantly, both polymorphisms
increased the risk of ALC in the Asian population with
a high OR for the disease exceeding 4.5 (27, 28). Con-
trary to the paper by Takamatsu et al. (27), we did not
include the IL1B q3953C/T polymorphism because it
does not alter in vitro protein secretion (37), and we
did not include the silent IL1B –511C allele. Instead,
we analyzed the IL1B –31T allele, which is in complete
LD with the IL1B –511C allele, creates a TATAA
sequence in the promoter and results in a five-fold
increase of IL1B transcription (24).
Selection of the appropriate cases and controls is a
major issue in genetic studies on ALC. In case-control
studies, individuals with the disease under investiga-
tion (cases) are compared to individuals who do not
have the disease, but who are thought to be compar-
able in other respects (controls). Inclusion of patients
with advanced ALC reduces the risk of misclassifica-
tion, increases phenotypic homogeneity and the
power to detect genetic association. Indeed, selection
of extreme cases, such as patients undergoing liver
transplantation, further increases the power of the
study but also inflates the estimation of population-
based parameters, such as population attributable
risk. However, it was not the purpose of our study to
assess this measure because such assessment would
require a significantly higher number of individuals
with ALC recruited in a population-based manner.
Daly and Day (38) advocated that control individu-
als in genetic studies should reveal a comparable
exposure to alcohol as cases. Compared to popula-
tion controls, use of ‘‘hypernormal’’ controls (healthy
heavy drinkers) would be expected to improve the
power by increasing the difference in susceptibility
allele frequency between cases and controls. How-
ever, this benefit is usually not substantial and is
counterweighted by the costs and effort of defining a
‘‘hypernormal’’ population (39). In our study, investi-
gating healthy German heavy drinkers did not yield a
positive association with an increased risk of ALC and
the frequency of the wIL1RN*2/*2; IL1B –31Tqx diplo-
type in this group was not significantly different from
that in German population controls. Taken together,
it does not seem to us that inclusion of ‘‘hypernor-
mal’’ controls is superior to population controls.
The discrepancy between our findings and the pre-
viously published studies (26–30, 35, 40) might be
explained by ethnical differences and/or the lack of
statistical power. Moreover, none of the studies
(26–30, 35, 40) included an independent validation
sample which should be implemented particularly in
smaller studies that are likely to be subject to a type
1 error which overestimates a genetic effect due to
chance (41). Verifying positive findings in an inde-
pendent validation sample helps to detect false asso-
ciations, as exemplified in our study in which a
seemingly positive association from a pilot study was
rejected by its subsequent validation in an additional
group of subjects with the same phenotype.
Also, genetic association studies are frequently
subject to type 2 errors (false negativity), because
polymorphisms are not causal and act only as pheno-
type modifiers. In our study, we maximized the power
to detect an association with an increased risk of ALC
by (i) selecting genes and polymorphisms that are
expected to have the highest possible effect size (pro-
tection against alcohol-induced liver injury in animal
knockout models, additive effect of IL1B –31T and
IL1RN*2 alleles on the secretion rate of IL-1b), (ii)
inclusion of patients with advanced ALC, and (iii)
inclusion of ‘‘hypernormal’’ controls. The design of
our study would enable us to detect biologically sig-
nificant associations if they exist. Our study was not
powered enough to detect OR below 2, although poly-
morphisms with a small effect size could act as dis-
ease modifiers and confer a measurable attributable
risk. However, their clinical significance is question-
able. In fact, they could hardly be used for predicting
the risk of ALC in ethanol-drinking individuals, which
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is the ultimate goal of identifying disease susceptibil-
ity markers.
In conclusion, although there is little doubt that
cytokine mediated immune reactions do play a role in
the pathogenesis of ALC, hereditary susceptibility
caused by variants in the corresponding genes seems
to be low, or at least such is the case in a CEU
population.
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